Berlin (pta041/16.05.2022/17:00) - TELES AG Informationstechnologien (ISIN DE000A289B07 / WKN A289B0) continues to grow significantly against the market. The pharmaceutical supply segment is proving to be the strongest growth driver.
The TELES-Group achieved sales revenues of EUR 19.5 million (previous year: EUR 540 thousand). The operating cash flow grew to EUR 2.2 million (previous year: EUR 125 thousand). Both are an expression of the great demand for the company's products.
The earnings situation of the TELES-Group improved significantly in the first quarter of 2022 compared to the same period of the previous year. Gross profit tripled to EUR 1.3 million (previous year: EUR 419 thousand) and thus exceeded the forecast.
The investment of EUR 383,000 primarily includes expenses for ongoing automation at EURO RX Arzneimittel GmbH. As of March 31, 2022, the financial resources were EUR 3 million (previous year: EUR 798 thousand) and offer a solid basis for further growth.
Personnel expenses increased by 121% to EUR 822 thousand (previous year: EUR 373 thousand) due to the integration of EURO RX Arzneimittel GmbH. Depreciation was EUR 95 thousand (previous year: EUR 22 thousand). Other operating income was EUR 49 thousand (previous year: EUR 0 thousand). With the increase in other operating expenses of EUR 444 thousand (previous year: EUR 142 thousand), EBITDA was EUR 180 thousand (previous year: EUR -58 thousand) and the consolidated result at EUR -51 thousand (previous year: EUR -109 thousand).
The balance sheet total of TELES increased by EUR 11.3 million compared to the previous year to EUR 14.4 million due to the larger current assets.
Chief Executive Officer(end)
|emitter:||TELES AG Informationstechnologien|
|contact person:||Oliver Olbrich|
|phone:||+49 30 399 28 00|
|stock exchanges:||regulated market in Frankfurt; free market in Dusseldorf, free market in Hamburg, free market in Munich, free market in Stuttgart; open market in Berlin|